<DOC>
	<DOC>NCT01989468</DOC>
	<brief_summary>The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFα) therapy.</brief_summary>
	<brief_title>24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria. Rheumatoid factor and anticyclic citrullinated peptide (CCP) antibodies negative. Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis. Inadequate control of symptoms with NSAID. Chest Xray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process. Subjects taking high potency opioid analgesics. Previous exposure to secukinumab or other biologic drug directly targeting interleukin17 (IL17) or IL17 receptor. Ongoing use of prohibited psoriasis treatments / medications. Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα. Previous treatment with any celldepleting therapies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>AIN457</keyword>
	<keyword>PsA</keyword>
	<keyword>ACR</keyword>
	<keyword>CASPAR</keyword>
	<keyword>PASDAS</keyword>
	<keyword>secukinumab</keyword>
	<keyword>autoinjector</keyword>
</DOC>